UBS Remains a Hold on Stevanato Group (STVN)
TipRanks (Wed, 9-Sep 7:38 AM ET)
Stevanato Group to Participate in Two Upcoming Investor Conferences
Business Wire (Tue, 8-Sep 4:05 PM ET)
Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026
Business Wire (Tue, 4-Aug 6:30 AM ET)
Business Wire (Thu, 30-Jul 6:30 AM ET)
Stevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026
Business Wire (Tue, 21-Jul 6:30 AM ET)
Market Chameleon (Wed, 4-Mar 4:28 AM ET)
Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.
Stevanato Group S.P.A. trades on the NYSE stock market under the symbol STVN.
As of September 9, 2026, STVN stock price declined to $20.25 with 1,293 million shares trading.
STVN has a beta of 1.46, meaning it tends to be more sensitive to market movements. STVN has a correlation of 0.21 to the broad based SPY ETF.
STVN has a market cap of $5.52 billion. This is considered a Mid Cap stock.
Last quarter Stevanato Group S.P.A. reported $351 million in Revenue and $.16 earnings per share. This fell short of revenue expectation by $-279,000 and exceeded earnings estimates by $.02.
In the last 3 years, STVN traded as high as $35.56 and as low as $12.89.
The top ETF exchange traded funds that STVN belongs to (by Net Assets): KOMP, NBSM, BCSM, SMLV, SCAP.
STVN has underperformed the market in the last year with a price return of -20.4% while the SPY ETF gained +18.9%. However, in the short term, STVN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +12.8% vs +3.6% return in SPY. But in the last 2 weeks, STVN shares have been beat by the market, returning -10.8% compared to an SPY return of -0.3%.
STVN support price is $19.81 and resistance is $20.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STVN shares will trade within this expected range on the day.